The global AL amyloidosis therapeutics market is slated to reach a valuation of USD 2.25 billion by the end of 2023. According to Future Market Insights, the market is projected to rise at a 7.3% CAGR until 2033, being valued at USD 4.56 billion.
The most common kind of systemic amyloidosis is the amyloid light chain (AL) amyloidosis, sometimes referred to as primary amyloidosis. Systemic light-chain (AL) amyloidosis was once thought to be an unstoppable deadly condition. The AL amyloidosis outlook was dismal prior to effective therapy for the fundamental plasma cell dyscrasia, with an average AL amyloidosis life expectancy of almost 13 months and to just 6 months for individuals with symptomatic cardiac dysfunction. Indicators of myocardial cell destruction and heart failure, that are exceedingly sensitive to cardiac dysfunction in amyloidosis, are the main focus of present AL amyloidosis staging techniques.
The purpose of AL amyloidosis therapy is to quickly decrease the plasma cell clone in order to increase amyloid reabsorption as well as restore organ function, hence enhancing patients' QOL, heart function, and survival. In the right patients, chemotherapy (both low and high dose) combined with autologous hematopoietic stem cell transplantation (ASCT) significantly lowers the formation of amyloid light chains. Melphalan, bortezomib and dexamethasone-based regimens should be used to treat patients who are ineligible for ASCT.
As one AL amyloidosis therapeutic approach, the National Comprehensive Cancer Network suggests high-dose melphalan followed by ASCT. Treatment for AL amyloidosis is very customized and should be focused on hematologic as well as cardiac response indicators as well as organ dysfunction, age, and regimen toxicity. Alkylator-based chemotherapy is beneficial for around two thirds of patients. Also, there are tests being conducted to determine the optimum way to use novel agents. Such developments are expected to people the demand in the market from 2023 to 2033.
| Data Points | Key Statistics |
|---|---|
| Anticipated Base Year Value (2022) | USD 2.1 billion |
| Expected Market Value (2023) | USD 2.25 billion |
| Projected Forecast Value (2033) | USD 4.56 billion |
| Global Growth Rate (2023 to 2033) | 7.3% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global AL amyloidosis therapeutics market grew at a CAGR of 5.2% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence. Although this condition is more common in adults above the age of 60 years and older, the growing geriatric population in both developed and emerging nations is also driving the demand in the global AL amyloidosis therapeutics market.
Also, the market for AL amyloidosis treatments is accelerating due to increased governmental and private sector funding, research, and development efforts. The development of healthcare technology and growing public awareness of rare illnesses are expected to support market expansion in the years to come. As a result, the global AL amyloidosis therapeutics market is expected to forecast a CAGR over 8% from 2023 to 2033.
Various biological advancements used in this therapy is driving the market expansion
The market for AL amyloidosis therapeutics is largely being driven by the rise in incidences of mutations in blood cell DNA and the prevalence of underlying plasma cell illnesses such as monoclonal gammopathy and multiple myeloma of uncertain significance.
Also, the widespread use of amyloid stabilizers, which stabilize the amyloid protein and stop it from building up in tissues and organs, is supporting the market's expansion. Moreover, the increasing use of innovative treatments that target the underlying causes of AL amyloidosis, such as immunomodulatory medications, proteasome inhibitors, monoclonal antibodies, etc. has considerably increased patient response times and lengthened progression-free life. This in turn is serving as yet another important component that promotes development.
The market is also expanding owing to the rising demand for high-dose chemotherapy, accompanied by autologous transplantation of stem cells, as a therapeutic option for patients admitted with AL amyloidosis. This therapy tries to enhance organ function by removing aberrant cells that generate amyloid protein. Moreover, continual improvements in diagnostic methods, such as the development of serum-free light chain tests as well as mass spectrometry, have made it possible to make diagnoses sooner, enabling quicker treatment to begin and improved control of disease-related problems. Hence, the market for AL amyloidosis therapeutics is anticipated to grow throughout the course of the projected period.
Principal Consultant
Lack of information and clinical studies is expected to impede the market growth
There is a shortage of epidemiological information on AL amyloidosis, and retrospective analysis reduces the validity of the data, which limits the market's potential growth. Additionally, the complex heterogeneity of the illnesses delays diagnosis, leading to severe disease (organ malfunction, including kidney, heart, and liver), lowering survival rates for AL amyloidosis, and acting as a roadblock to the expansion of the AL amyloidosis therapeutics market.
Clinical studies for AL amyloidosis therapeutics are also difficult to conduct successfully because of low patient recruitment as well as a lack of strictly delineated new outcomes. The participation of the kidney and heart systems results in expensive medical care. Moreover, the anticipated releases will probably cost more than myeloma-based medications, which may limit the accessibility and affordability of the AL amyloidosis therapies. Additionally, the function of upfront ASCT in various eligible patients has to be addressed in the era of daratumumab-based therapy. The aforementioned issues thus restrict the growth of the AL amyloidosis therapeutics market.
Rising incidence of amyloidosis cases along with innovative products will boost the growth
During the forecast period, the North American market for AL amyloidosis therapeutics is expected to be the most volatile one. As per Future Market Insights, this region is expected to proliferate with a robust CAGR of 7.9% from 2023 to 2033.
The adoption of innovative therapies surged as a result of the prospective release of pipeline medications, and its dominating market share is also largely due to the high expense of healthcare in the United States. Around 3,900 new instances of AL amyloidosis are detected each year in the United States, making it the most prevalent kind.
This disease variant's diagnostic age is often in the mid-60s. Its yearly incidence in North American nations is roughly 15 instances per million persons, or about one-fifth that of myeloma, a blood cancer brought on by clonal plasma cells found in the bone marrow. Moreover, it can be challenging to diagnose since symptoms including weariness, paresthesia, edema, and weight loss frequently coexist with those of other prevalent illnesses. Hence, during the forecast period, the North American region can be expected to show a significant growth rate, acquiring a global market share of 39% in the year 2023.
Enhanced healthcare facilities and strong patient pool to accelerate growth
During the forecast period, the Asia Pacific market for AL amyloidosis therapeutics is expected to garner a steady CAGR of 7.6%. The Asia Pacific AL amyloidosis therapeutics market is anticipated to grow quickly throughout the time of forecasting. This is because two of the three late-stage medications have received approval in Asia Pacific to treat amyloidosis. Due to supportive government policies, enhanced healthcare infrastructure, and greater investment, emerging markets for amyloidosis, such as China and India, are anticipated to have enticing development throughout the projection period.
The strong need for economical healthcare in these nations with big populations and low per capita incomes will fuel the growth of chemotherapy generic versions in this market. Alternatives for curative treatments with increased effectiveness are desperately needed. Hence, factors such as these are expected to accelerate the growth in the regional market from 2023 to 2033.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The chemotherapy segment will gain the dominant market share
Over the course of the forecast period, the chemotherapy segment by treatment type is anticipated to occupy a significant share of the global AL amyloidosis therapeutics market. In 2023, this category is anticipated to dominate with a 53% revenue share.
Anti-cancer treatments or chemotherapy are used to treat AL amyloidosis because they slow the proliferation of the aberrant cells that produce amyloid. Such factors are expected to accelerate the growth prospects for AL amyloidosis therapeutics from 2023 to 2033.
Hospital pharmacies segment will demand during the forecast period
Future Market Insights' study indicates that the hospital pharmacy segment would expand throughout the projected period. From 2023 to 2033, it is predicted that this market segment would have a 25% share of the global market.
Patients who are diagnosed with AL amyloidosis are mostly being treated in the hospitals under the supervision of the specialized doctors. With such patients, no doctor takes the risk of the treating them at home. Hence, as the treatment is being conducted in the hospitals itself, most of the medications and therapies are provided by the hospitals.
The start-ups in this sector aim to use a number of techniques, such as the launch of new products and acquisitions, to improve their market positions internationally.
The launch of Darzalex Faspro by Genmab as well as Janssen Biotech, as well as AstraZeneca's purchase of Caelum Biosciences in 2021, are two examples of how significant industry players are increasing their understanding of the disease and working together. One of the main drivers of the AL amyloidosis therapeutics market growth is the strong pipeline with innovative, first-in-class medicines for the treatment of the disease.
Some of the important developments of the key players of the market are
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 7.3% from 2023 to 2033 |
| Market value in 2023 | USD 2.25 billion |
| Market value in 2033 | USD 4.56 billion |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | USD Billion for Value and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Treatment, Drug, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, United Kingdom, Spain, Germany, Italy, France, Rest of Europe, China, Japan, South Korea, India, South Africa, GCC Countries |
| Key Companies Profiled | Janssen Pharmaceutical; Prothena; Alexion Pharmaceuticals; Oncopeptides AB; Bristol-Myers Squibb; GlaxoSmithKline Pharmaceuticals Ltd; Celgene Corp; Eidos Therapeutics, Inc.; Corino Therapeutics, Inc.; Spectrum Pharmaceuticals, Inc.; Pfizer |
| Customization Scope | Available on Request |
The market is valued at USD 2.25 billion in 2023.
The market rose at a 5.2% CAGR from 2018 to 2022.
The market is forecast to secure a CAGR of 7.3% through 2033.
The market is expected to reach USD 4.56 billion by 2033.
North America is expected to accumulate a CAGR of 7.9% until 2033.
1. Executive Summary | AL Amyloidosis Therapeutics Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Chemotherapy 5.2. Supportive Care 5.3. Surgery 5.4. Stem Cell Transplant 5.5. Targeted Therapy 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drugs 6.1. Transthyretin Transport Inhibitor 6.2. Immunomodulatory Drugs 6.3. Monoclonal Antibodies 6.4. Proteasome Inhibitors 6.5. Others 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Hospital Pharmacies 7.2. Retail Pharmacies 7.3. Online Pharmacies 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. Asia Pacific 8.5. Middle East and Africa 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Key Countries Market Analysis 15. Market Structure Analysis 16. Competition Analysis 16.1. Janssen Pharmaceutical 16.2. Prothena 16.3. Alexion Pharmaceuticals 16.4. Oncopeptides AB 16.5. Bristol-Myers Squibb 16.6. GlaxoSmithKline Pharmaceuticals Ltd 16.7. Celgene Corp 16.8. Eidos Therapeutics, Inc. 16.9. Corino Therapeutics, Inc. 16.10. Spectrum Pharmaceuticals, Inc. 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
AL Amyloidosis Therapeutics Market
